These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 30690076)
1. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience. Louie RJ; Perez MC; Jajja MR; Sun J; Collichio F; Delman KA; Lowe M; Sarnaik AA; Zager JS; Ollila DW J Am Coll Surg; 2019 Apr; 228(4):644-649. PubMed ID: 30690076 [TBL] [Abstract][Full Text] [Related]
2. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience. Perez MC; Miura JT; Naqvi SMH; Kim Y; Holstein A; Lee D; Sarnaik AA; Zager JS Ann Surg Oncol; 2018 Dec; 25(13):3960-3965. PubMed ID: 30298318 [TBL] [Abstract][Full Text] [Related]
3. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey. Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143 [TBL] [Abstract][Full Text] [Related]
4. Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease. MacArthur TA; Fahy AS; Jakub JW Am Surg; 2021 Jun; 87(6):849-854. PubMed ID: 34060947 [TBL] [Abstract][Full Text] [Related]
5. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039 [TBL] [Abstract][Full Text] [Related]
6. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145 [TBL] [Abstract][Full Text] [Related]
7. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058 [TBL] [Abstract][Full Text] [Related]
8. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial. Monga V; Miller BJ; Tanas M; Boukhar S; Allen B; Anderson C; Stephens L; Hartwig S; Varga S; Houtman J; Wang L; Zhang W; Jaber O; Thomason J; Kuehn D; Rajput M; Metz C; Zamba KD; Mott S; Abanonu C; Bhatia S; Milhem M J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330766 [TBL] [Abstract][Full Text] [Related]
10. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. Chesney J; Awasthi S; Curti B; Hutchins L; Linette G; Triozzi P; Tan MCB; Brown RE; Nemunaitis J; Whitman E; Windham C; Lutzky J; Downey GF; Batty N; Amatruda T Melanoma Res; 2018 Feb; 28(1):44-51. PubMed ID: 29176501 [TBL] [Abstract][Full Text] [Related]
11. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. Sun L; Funchain P; Song JM; Rayman P; Tannenbaum C; Ko J; Mcnamara M; Marcela Diaz-Montero C; Gastman B J Immunother Cancer; 2018 May; 6(1):36. PubMed ID: 29764498 [TBL] [Abstract][Full Text] [Related]
12. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases. Everett AS; Pavlidakey PG; Contreras CM; De Los Santos JF; Kim JY; McKee SB; Kaufman HL; Conry RM J Cutan Pathol; 2018 Jan; 45(1):48-53. PubMed ID: 28940544 [TBL] [Abstract][Full Text] [Related]
17. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. Carr MJ; Sun J; DePalo D; Rothermel LD; Song Y; Straker RJ; Baecher K; Louie RJ; Stahlie EHA; Wright GP; Naqvi SMH; Kim Y; Sarnaik AA; Karakousis GC; Lowe MC; Delman KA; van Akkooi ACJ; Ollila DW; Collichio F; Zager JS Ann Surg Oncol; 2022 Feb; 29(2):791-801. PubMed ID: 34648098 [TBL] [Abstract][Full Text] [Related]
18. The safety of talimogene laherparepvec for the treatment of advanced melanoma. Gangi A; Zager JS Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216 [TBL] [Abstract][Full Text] [Related]
19. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab. Afzal MZ; Shirai K J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044 [TBL] [Abstract][Full Text] [Related]
20. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report. Chitnis SD; Seim NB; Kendra K J Med Case Rep; 2024 May; 18(1):257. PubMed ID: 38778387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]